Overview

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong Hengrui Pharmaceutical Co., Ltd